Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Small Cell Carcinoma of the Lung
Sponsor: Burzynski Research Institute
Terminated
slow accrual
Other terminated trials from Burzynski Research Institute
A PHASE2 clinical study on Small Cell Lung Cancer Extensive Stage, this trial is terminated or withdrawn. The trial is conducted by Burzynski Research Institute and has accumulated 6 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
▶ Show 1 earlier version
-
Jan 2017 — Oct 2017 [monthly]
Unknown Status PHASE2
First recorded
Mar 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Burzynski Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .